Vesugen (KED)

The 2016 PubMed-indexed paper names KED as Lys-Glu-Asp, while the 2014 paper refers to Vesugen in endothelial-cell research. Those source designations establish what the publications discuss; they do not verify the identity, purity, or analytical characterization of any particular research material or batch.

The conceptual artwork is an editorial identity illustration. It is not a chemically exact molecular structure, product analysis, assay, or experimental result. Keep the compound name and source-specific preparation attached to each study record.

• Reported sequence in the cited KED paper: Lys-Glu-Asp (KED)
• Vesugen is discussed in vascular/endothelial research literature
• A publication’s test-article description is not batch-specific verification

The PubMed abstract reports that Vesugen and D-7 stimulated the proliferation-associated protein Ki-67 in the described cell-culture systems. It also reports molecular-docking analyses involving a region of the MKI67 promoter. The docking result is computational evidence, not a direct measurement of promoter binding in a living system or proof of a complete regulatory mechanism.

These are source-specific in-vitro findings. Read the full methods and the distinction between the cultured-cell measurements and the authors’ proposed interpretation. The accompanying art is a conceptual research scene, not microscopy or assay data.

• Reported model: tissue-specific and dissociated endothelial-cell cultures
• Reported measurement: Ki-67, a proliferation-associated protein
• Promoter interaction was examined by molecular docking; this is not direct in-vivo confirmation

The abstract describes docking analyses that placed Vesugen and D-7 against a core promoter sequence associated with MKI67. This is a computationally generated interaction hypothesis. It should not be presented as direct experimental confirmation of promoter occupancy, gene regulation in a living organism, or a validated general mechanism.

The 2016 paper presents a separate in-vitro investigation of KED and endothelial signaling molecules in normal, atherosclerotic, and restenotic endothelial contexts. Its cellular expression observations and the earlier promoter-docking analysis address different questions; one cannot be substituted for the other.

• Docking models generate hypotheses; they do not alone establish molecular binding in vivo
• MKI67 is associated with the Ki-67 protein measured in the 2014 study
• Keep the 2014 culture/docking record separate from the 2016 endothelial expression study

The PubMed abstract describes work on signaling-molecule expression in normal, atherosclerotic, and restenotic endothelium in vitro. It reports observations involving endothelin-1, connexin expression, and sirtuin-1. These are reported cell-model findings from that paper; they are not clinical outcomes and do not establish that every proposed vascular mechanism is confirmed.

A 2021 paper separately studied KED alongside EDR in cellular amyloid-synaptotoxicity experiments and a 5xFAD mouse model. It concerns a different research question and experimental system. The records should remain in separate evidence lanes rather than being combined into one broad conclusion about Vesugen.

• 2016: in-vitro endothelial contexts and expression endpoints
• 2021: separate cellular and 5xFAD mouse-model research involving KED and EDR
• Different models and endpoints cannot be treated as interchangeable evidence

The linked publications describe cultured-cell work, a molecular-docking hypothesis, and separate animal-model research. These source types have different evidentiary roles. The abstracts do not establish a clinical benefit, a complete causal pathway, or generalizability beyond the tested preparations and models.

A careful review checks test-article identity, model, comparator, assay, endpoint, replication, and independent confirmation. The closing illustration deliberately separates records and leaves questions open; it is not molecular docking output, experimental data, or an outcome prediction.

• Keep each reported observation attached to its source, model, and method
• Separate direct measurement from computational proposal and author interpretation
• Do not infer a clinical effect or universal mechanism from these records
• Treat replication and independent confirmation as open evidence questions